Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000902664-25-002765·Adage Capital Management, L.P.
Schedule 13D ownership disclosure
CRESCENT BIOPHARMA INC.
Ordinary Shares, par value $0.001 per share · CUSIP: 38000Q201
Event date: 2025-06-20
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Adage Capital Management, L.P.Reported CIK 0001535978
Shares: 50,912.00 · Class: 0.37%
- Robert AtchinsonReported CIK 0001403404
Shares: 50,912.00 · Class: 0.37%
- Phillip GrossReported CIK 0001403413
Shares: 50,912.00 · Class: 0.37%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-002765
- Form type
- SCHEDULE 13D/A
- Filer
- Adage Capital Management, L.P.
- CIK
- CIK 1535978
- Filed
- Jun 20, 2025
- Reporting period
- Jun 20, 2025
- Description
- Schedule 13D beneficial ownership